- Home
- GNW vs ACAD Comparison
GNW vs ACAD Comparison
Compare GNW & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNW
- ACAD
- Stock Information
- Founded
- GNW 1871
- ACAD 1993
- Country
- GNW United States
- ACAD United States
- Employees
- GNW N/A
- ACAD N/A
- Industry
- GNW Life Insurance
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- GNW Finance
- ACAD Health Care
- Exchange
- GNW Nasdaq
- ACAD Nasdaq
- Market Cap
- GNW 2.9B
- ACAD 2.8B
- IPO Year
- GNW 2004
- ACAD 2004
- Fundamental
- Price
- GNW $6.72
- ACAD $14.73
- Analyst Decision
- GNW
- ACAD Buy
- Analyst Count
- GNW 0
- ACAD 16
- Target Price
- GNW N/A
- ACAD $23.93
- AVG Volume (30 Days)
- GNW 7.4M
- ACAD 1.7M
- Earning Date
- GNW 04-30-2025
- ACAD 05-07-2025
- Dividend Yield
- GNW N/A
- ACAD N/A
- EPS Growth
- GNW 323.28
- ACAD N/A
- EPS
- GNW 0.68
- ACAD 1.36
- Revenue
- GNW $7,295,000,000.00
- ACAD $957,797,000.00
- Revenue This Year
- GNW N/A
- ACAD $13.07
- Revenue Next Year
- GNW N/A
- ACAD $9.88
- P/E Ratio
- GNW $9.69
- ACAD $10.80
- Revenue Growth
- GNW N/A
- ACAD 31.85
- 52 Week Low
- GNW $5.87
- ACAD $13.40
- 52 Week High
- GNW $7.90
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- GNW 50.18
- ACAD 40.66
- Support Level
- GNW $6.55
- ACAD $14.44
- Resistance Level
- GNW $6.78
- ACAD $14.98
- Average True Range (ATR)
- GNW 0.30
- ACAD 0.78
- MACD
- GNW 0.02
- ACAD 0.09
- Stochastic Oscillator
- GNW 89.17
- ACAD 57.83
About GNW Genworth Financial Inc
Genworth Financial is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. most of the revenue is generated by the Long-Term Care Insurance segment. The company earns most of its revenue in the United States.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.